The news of a safe, effective vaccine has been a rare bright spot during the yearlong fight against the coronavirus. Two pharmaceutical companies, Pfizer and Moderna, are racing toward emergency authorization for their vaccines, both of which boast an efficacy rate of more than 94 percent. That authorization could come as soon as a few days from now, and the first vaccinations could begin later this month.
A line for the vaccine is already forming, but plenty of questions remain. Recently, the nonprofit Math for America, a New York-based organization for math and science teachers, hosted an information-rich webinar about the coronavirus and the mechanics of developing effective vaccines with Dr. Florian Krammer, a professor of vaccinology at the Icahn School of Medicine at Mount Sinai in New York, who has amassed a large Twitter following in recent months for his discussions on the science of vaccines.
…..
The news of a safe, effective vaccine has been a rare bright spot during the yearlong fight against the coronavirus. Two pharmaceutical companies, Pfizer and Moderna, are racing toward emergency authorization for their vaccines, both of which boast an efficacy rate of more than 94 percent. That authorization could come as soon as a few days from now, and the first vaccinations could begin later this month.
A line for the vaccine is already forming, but plenty of questions remain. Recently, the nonprofit Math for America, a New York-based organization for math and science teachers, hosted an information-rich webinar about the coronavirus and the mechanics of developing effective vaccines with Dr. Florian Krammer, a professor of vaccinology at the Icahn School of Medicine at Mount Sinai in New York, who has amassed a large Twitter following in recent months for his discussions on the science of vaccines.
…..